[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368845-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368845-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","occurrence-of-dmmrmsi-h-tumor-during-follow-up-in-lynch-syndrome-patients-treated-with-immune-checkpoint-inhibitors-for-metastatic-digestive-cancer-between-2015-and-2024-a-retrospective-analysis-of-a-monocentric-prospective-cohort-study","Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024 - a retrospective analysis of a monocentric prospective cohort study","","Immune checkpoint inhibitors have reshaped treatment for mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer in Lynch syndrome, yet the risk profile for subsequent metachronous tumors and colorectal polyp development after ICI exposure remains unclear. A single-center retrospective review evaluated 93 Lynch syndrome patients from the ImmunoMSI prospective cohort, treated with ICIs for index metastatic gastrointestinal cancer from 2015 to 2024, focusing on cumulative metachronous cancers and de novo preneoplastic polyps. After follow-up, patients showed measurable risk even following responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/occurrence-of-dmmrmsi-h-tumor-during-follow-up-in-lynch-syndrome-patients-treated-with-immune-checkpoint-inhibitors-for-metastatic-digestive-cancer-between-2015-and-2024-a-retrospective-analysis-of-a-monocentric-prospective-cohort-study/368845/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/occurrence-of-dmmrmsi-h-tumor-during-follow-up-in-lynch-syndrome-patients-treated-with-immune-checkpoint-inhibitors-for-metastatic-digestive-cancer-between-2015-and-2024-a-retrospective-analysis-of-a-monocentric-prospective-cohort-study/368845.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study question regarding immune checkpoint inhibitors in Lynch syndrome?","Question",{"text":63,"@type":64},"The study assessed how often Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic dMMR/MSI-H gastrointestinal cancer develop metachronous dMMR/MSI-H tumors and de novo preneoplastic colorectal polyps.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many Lynch syndrome patients and what time frame were included?",{"text":68,"@type":64},"Ninety-three Lynch syndrome patients were included, selected from the prospective ImmunoMSI cohort, with index metastatic gastrointestinal cancer treated between February 2015 and April 2024.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were measured as primary and secondary endpoints?",{"text":72,"@type":64},"Primary and secondary outcomes were the cumulative risks of metachronous dMMR/MSI-H cancer(s) and de novo colorectal preneoplastic polyps, respectively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368845,1790195399,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","ORIGINAL ARTICLE  \nOccurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: a retrospective analysis of a monocentric prospective cohort study  \nA. Pellat1 , 2 ∗, C. Loisel3 , 4, J. Metras5, J. H. Lefevre6 , 7, Y. Parc6 , 7, R. Cohen3 , 6, T. Samaille3, A. Perrier5, A. Dardenne3 , 5 , 7 &  \nT. André3 , 6  \n1Gastroenterology, Digestive Endoscopy and Digestive Oncology Department, Cochin Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris; 2Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Centre for Research in Epidemiology and Statistics (CRESS), Paris; 3Saint Antoine Hospital, Assistance Publique Hôpitaux de Paris (APHP), Sorbonne Université, Paris; 4Gastroenterology Department, Hôpital Pontchaillou, Rennes 1 University, Rennes; 5Department of Genetics, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris; 6Unité Mixte de Recherche Scientifique 938, SIRIC CURAMUS, Paris; 7Department of Digestive Surgery, Saint Antoine Hospital, Assistance Publique Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France  \nAvailable online xxx  \nBackground: Immune checkpoint inhibitors (ICIs) represent a paradigm shift and a therapeutic revolution in the management of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), and therefore for patients with Lynch syndrome (LS) . The risk of developing metachronous cancers and colorectal polyps in a population of LS patients treated with ICI(s) is not well understood.  \nMaterials and methods: In a single-center cohort study, we retrospectively reviewed 93 LS patients from the prospective ‘ImmunoMSI’ cohort, who were diagnosed with dMMR/MSI-H gastrointestinal cancer and were treated with ICIs for index metastatic gastrointestinal cancer between February 2015 and April 2024. The primary and secondary outcomes were the cumulative risks of metachronous dMMR/MSI-H cancer(s) and de novo colorectal preneoplastic polyps, respectively.  \nResults: The median age at diagnosis was 62 years (range 26-77 years) . Most patients carried a germline pathogenic variant in the MSH2/EPCAM (47%) or MLH1 (30%) genes. The majority presented CRC as their index cancer (83%), followed by cancers of the small intestine (6%), stomach (4%), and pancreas (4%) . During or after treatment with ICI(s), 8 out of 93 patients (8%) developed a total of 9 dMMR/MSI-H cancers, including urothelial (n = 4), colorectal (n = 3), pancreatic (n = 1), and skin cancer (n = 1) . All patients who developed metachronous cancers had either a complete or partial response to ICI(s) treatment for their index cancer. During a median follow-up of 47.8 months, 44 patients had colonoscopies, and 17 (39%) developed de novo preneoplastic polyps.  \nConclusions: Our results show that patients with LS treated with ICIs for dMMR/MSI-H metastatic digestive cancers are at risk of developing metachronous dMMR/MSI-H cancers and preneoplastic colorectal polyps. This underlines the importance of dedicated long-term follow-up in this population, even after successful ICI treatment for their first digestive cancer.  \nKey words: Lynch syndrome, dMMR/MSI-H cancer, gastrointestinal cancer, colorectal polyps, immune checkpoint inhibitors  \n*Correspondence to: Dr Anna Pellat, Service de Gastroentérologie, d’Endoscopie Digestive et d’Oncologie Digestive, Hôpital Cochin, AP-HP Centre, 75014 Paris, France; Faculté de Médecine, Université Paris Cité, 75006 Paris, France. Tel: +33-158411921  \nE-mail: [anna.pellat@aphp.fr](anna.pellat@aphp.fr) (A. Pellat).  \n2059-7029/© 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nINTRODUCTION  \nLynch syndrome","cbCaintdQM9dujNy","https://ap.wps.com/l/cbCaintdQM9dujNy","pdf",479935,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What was the study question regarding immune checkpoint inhibitors in Lynch syndrome?\",\"answer\":\"The study assessed how often Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic dMMR/MSI-H gastrointestinal cancer develop metachronous dMMR/MSI-H tumors and de novo preneoplastic colorectal polyps.\"},{\"question\":\"How many Lynch syndrome patients and what time frame were included?\",\"answer\":\"Ninety-three Lynch syndrome patients were included, selected from the prospective ImmunoMSI cohort, with index metastatic gastrointestinal cancer treated between February 2015 and April 2024.\"},{\"question\":\"What outcomes were measured as primary and secondary endpoints?\",\"answer\":\"Primary and secondary outcomes were the cumulative risks of metachronous dMMR/MSI-H cancer(s) and de novo colorectal preneoplastic polyps, respectively.\"}]","Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024 - a retrospective analysis of a monocentric prospective cohort study | PDF",1790178908,18,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/207a258f199770361af703b1adb05a57.webp",983,1269,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a74a2426d761fad93d6ac7df5daccb5a.webp",982,1268,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3cae8c0c757844ab8e722f0af14b30c.webp",981,1266,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6d9f287df7993db65d5ede63ce43d4b.webp",980,1265]